TP53-mutations (n = 81), ESR1 (n = 82), PIK3CA-mutations (n = 53), and AKT-mutations (n = 31) have most frequently been assessed to evaluate response to therapy using ctDNA in patients with breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.